144 ·Filed Jun 25, 2026

PHVS

Pharvaris N.V.
NEUTRAL
Impact 2/10
Horizondays Processed3mo ago SEC0001950047-26-006503
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

No new directional signal — this is a pre-scheduled 10b5-1 plan fill. The plan has been executing steadily since April 2026; this filing adds one more trade within the same program. Monitor for any unexpected acceleration outside the plan or filings by other insiders. The stock's 90% buy-rated analyst consensus offsets any concern from a routine planned sale.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
PHVS ▲ +5.91% at T+60d
NEUTRAL call ✓ call won +5.91% · α vs SPY +1.42% · entry $34.01 → $36.02
Entry anchored
Jun 25, 03:59 PM ET
via exchange tick
T+1d
+2.06%
call +2.06% · α +0.41%
$34.71
settled 3mo ago
T+5d
-0.44%
call -0.44% · α -2.61%
$33.86
settled 3mo ago
T+20d
-2.21%
call -2.21% · α -3.47%
$33.26
settled 2mo ago
T+60d
+5.91%
call +5.91% · α +1.42%
$36.02
settled 11d ago

Price Chart

Loading chart...

Executive Summary

Director/10%-owner Lu Peng filed a Form 144 notice to sell 15,000 common shares valued at approximately $499,350. The sale is part of a pre-arranged 10b5-1 plan, with recent plan sales in April, May, and June 2026 already executed. As a structured plan sale, this filing signals no new opportunistic insider conviction — it is a routine step within an existing sell program.

Key Facts

  • Lu Peng filed Form 144 to sell 15,000 shares, estimated value ~$499,350.
  • The sale is under a 10b5-1 trading plan adopted August 19, 2025.
  • Plan sales have been ongoing: 7,001 shares on Apr 22, 100 on Apr 23, 3,733 on Apr 29, 15,000 on Apr 30, 14,166 on May 1, and 300 on Jun 18 at prices from ~$25 to ~$34.
  • Morgan Stanley Smith Barney is the broker handling the planned sales.
  • PHVS has $2.3B market cap with strong analyst consensus (90% bullish, 9 Strong Buy, 9 Buy, 2 Hold).

Financial Impact

~$499,350 in aggregate potential proceeds from 15,000 shares at ~$33.29 per share implied by filing

stock supply

Risk Factors

  • Multiple insiders or unplanned sales could shift sentiment, but this standalone 144 is low-risk.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-006503
Document: 0001950047-26-006503-index.html0001950047-26-006503
Document: 0001950047-26-006503.txt0001950047-26-006503
37 reports for PHVS
Performance horizon
90% Hit rate 9 of 10 directional calls best @ T+60▲ +21.31%Mar 20, 2026
Filters
Rows
Reports for PHVS — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
BEARISH ★ 5/10
$38.06 $36.37▲ +4.44%▲ +5.26%$31.07 (+18.38%)
Sep 14, 2026
17d ago
144
NEUTRAL ★ 2/10
$38.06 $35.20▼ −7.51%▼ −9.63%$31.07 (−18.38%)
Sep 14, 2026
18d ago
Insider Cluster
NEUTRAL ★ 3/10
$38.86 $36.02▼ −7.31%▼ −7.41%$31.07 (−20.06%)
Sep 11, 2026
21d ago
Insider Cluster
NEUTRAL ★ 3/10
$38.02 $36.37▼ −4.34%▼ −4.12%$31.07 (−18.29%)
Sep 8, 2026
24d ago
6-K
BULLISH ★ 8/10
$37.84 $38.86▲ +2.70%▲ +3.36%$31.07 (−17.90%)
Aug 12, 2026
7w ago
6-K
NEUTRAL ★ 6/10
$36.46 $36.27▼ −0.52%▼ −0.08%$31.07 (−14.80%)
Aug 12, 2026
7w ago
Press Release
BULLISH ★ 7/10
$36.46 $36.27▼ −0.52%▼ −0.08%$31.07 (−14.80%)
Aug 6, 2026
8w ago
Press Release
NEUTRAL ★ 4/10
$34.45 $34.04▼ −1.19%▼ −2.40%$31.07 (−9.83%)
Jul 6, 2026
12w ago
Press Release
BULLISH ★ 6/10
$33.22 $35.07▲ +5.57%▲ +5.08%$31.07 (−6.49%)
Jul 1, 2026
13w ago
Insider Cluster
NEUTRAL ★ 3/10
$33.86 $35.96▲ +6.20%▲ +5.27%$31.07 (−8.25%)
Showing 10 of 37

US Market Status

Market Open — Closes in 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access